IBA-11

IBA-11 binds to CRBN with an IC₅₀ of 2285 nM in a cell-free TR-FRET assay^[1].
IBA-11 potently inhibits the viability of MV-4-11 cells with an IC₅₀ of 82.11 nM, and shows minimal activity in MM.1S and Mino cells^[1].
IBA-11 (0.1-2.5 nM; 8 h) induces dose-dependent degradation of CK1α, but not IKZF1/2/3 or GSPT1, in MV-4-11 and Mino cells^[1].
IBA-11 (500 nM; 2-16 h) induces rapid, near-complete degradation of CK1α in Mino cells within 2 h^[1].
IBA-11 (500 nM; 3 h) induced CK1α degradation in Mino cells is dependent on the CRBN-mediated ubiquitin-proteasome system, as confirmed by rescue with MLN4924 (HY-70062), PS341 (HY-10227), and MG132 (HY-13259) ^[1].
IBA-11 (0.2-2 μM) induced CK1α degradation is strictly CRBN-dependent, as degradation is abolished in CRBN-knockout HEK293T cells^[1].
IBA-11 has favorable in vitro metabolic stability in rat liver microsomes and a low risk of cardiac toxicity, as indicated by minimal hERG inhibition (IC₅₀ >40 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.